JP2015514110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514110A5 JP2015514110A5 JP2015504677A JP2015504677A JP2015514110A5 JP 2015514110 A5 JP2015514110 A5 JP 2015514110A5 JP 2015504677 A JP2015504677 A JP 2015504677A JP 2015504677 A JP2015504677 A JP 2015504677A JP 2015514110 A5 JP2015514110 A5 JP 2015514110A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- hla
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 40
- 102000036639 antigens Human genes 0.000 claims 40
- 108091007433 antigens Proteins 0.000 claims 40
- 239000012634 fragment Substances 0.000 claims 40
- 102000006390 HLA-B Antigens Human genes 0.000 claims 30
- 108010058607 HLA-B Antigens Proteins 0.000 claims 30
- 238000006467 substitution reaction Methods 0.000 claims 30
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 25
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 25
- 150000001413 amino acids Chemical class 0.000 claims 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical group OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 229930195721 D-histidine Natural products 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000037855 acute anterior uveitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618969P | 2012-04-02 | 2012-04-02 | |
| US61/618,969 | 2012-04-02 | ||
| US201361778703P | 2013-03-13 | 2013-03-13 | |
| US61/778,703 | 2013-03-13 | ||
| PCT/US2013/034952 WO2013152001A2 (en) | 2012-04-02 | 2013-04-02 | Anti-hla-b*27 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514110A JP2015514110A (ja) | 2015-05-18 |
| JP2015514110A5 true JP2015514110A5 (OSRAM) | 2016-05-26 |
| JP6320993B2 JP6320993B2 (ja) | 2018-05-09 |
Family
ID=48093122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504677A Active JP6320993B2 (ja) | 2012-04-02 | 2013-04-02 | 抗ｈｌａ−ｂ＊２７抗体およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9790273B2 (OSRAM) |
| EP (1) | EP2834272B1 (OSRAM) |
| JP (1) | JP6320993B2 (OSRAM) |
| KR (1) | KR20150003256A (OSRAM) |
| CN (1) | CN104169302A (OSRAM) |
| AR (1) | AR090585A1 (OSRAM) |
| AU (1) | AU2013243644C1 (OSRAM) |
| BR (1) | BR112014024622A2 (OSRAM) |
| CA (1) | CA2868907C (OSRAM) |
| CL (1) | CL2014002631A1 (OSRAM) |
| CO (1) | CO7121320A2 (OSRAM) |
| EA (1) | EA201491827A1 (OSRAM) |
| HK (1) | HK1207092A1 (OSRAM) |
| IL (2) | IL234707A0 (OSRAM) |
| MX (1) | MX365690B (OSRAM) |
| MY (1) | MY171180A (OSRAM) |
| NZ (1) | NZ700650A (OSRAM) |
| PH (1) | PH12014502184A1 (OSRAM) |
| SG (2) | SG11201405759UA (OSRAM) |
| TW (1) | TWI619729B (OSRAM) |
| UY (1) | UY34721A (OSRAM) |
| WO (1) | WO2013152001A2 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| BR112013013354A2 (pt) | 2010-11-30 | 2020-10-06 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente |
| EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
| EP4011913A1 (en) | 2011-06-30 | 2022-06-15 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| CN104080909A (zh) | 2011-11-30 | 2014-10-01 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CN116376983A (zh) | 2012-07-27 | 2023-07-04 | 希望之城 | 一种递送ul128复合体和预防cmv感染的mva疫苗 |
| JP6501521B2 (ja) | 2012-08-24 | 2019-04-17 | 中外製薬株式会社 | ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体 |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| KR102249779B1 (ko) | 2012-12-27 | 2021-05-07 | 추가이 세이야쿠 가부시키가이샤 | 헤테로이량화 폴리펩티드 |
| CA2908350C (en) | 2013-04-02 | 2023-08-08 | Futa Mimoto | Fc region variant |
| TWI617580B (zh) * | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| EP3253407B1 (en) * | 2015-02-04 | 2020-04-22 | Universität Zürich | Use of hla-b27 homodimers for cancer treatment |
| CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用 |
| CA2977106A1 (en) | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| EP3341738A4 (en) | 2015-08-24 | 2019-02-27 | University of Cincinnati | METHOD AND COMPOSITIONS FOR DETECTING FC RECEPTOR BINDING ACTIVITY OF ANTIBODIES |
| EP3347045A4 (en) | 2015-09-10 | 2019-08-28 | City of Hope | MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR |
| WO2017104783A1 (en) * | 2015-12-18 | 2017-06-22 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| IL259256B2 (en) * | 2015-12-18 | 2023-02-01 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| WO2017153438A1 (en) | 2016-03-08 | 2017-09-14 | Universität Zürich | Hla-b57 open conformers |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Ｉｌ−８関連疾患の治療用又は予防用組成物 |
| CA3031605A1 (en) | 2016-08-10 | 2018-02-15 | Universitat Zurich | Mhc class ia open conformers |
| US11608374B2 (en) | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| US20200114022A1 (en) * | 2017-03-31 | 2020-04-16 | Alma Bio Therapeutics | Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same |
| JP2020524512A (ja) | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
| EP3710589A4 (en) | 2017-11-14 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | ANTI-C1S ANTIBODIES AND METHOD OF USING |
| CN108486226B (zh) * | 2018-04-01 | 2022-04-12 | 广东辉锦创兴生物医学科技有限公司 | Hla-b27等位基因的检测试剂盒及其应用 |
| SG10202106830VA (en) | 2018-08-10 | 2021-08-30 | Chugai Pharmaceutical Co Ltd | Anti-cd137 antigen-binding molecule and utilization thereof |
| EP3941489A4 (en) * | 2019-03-21 | 2022-12-28 | Gamida-Cell Ltd. | EXTENDED NK CELL FRACTIONS SUITABLE FOR POLYTHERAPY TRANSPLANTATION |
| CA3137649A1 (en) | 2019-05-15 | 2020-11-19 | Chugai Seiyaku Kabushiki Kaisha | An antigen-binding molecule, a pharmaceutical composition, and a method |
| CN111175490A (zh) * | 2020-01-19 | 2020-05-19 | 泛肽生物科技(浙江)有限公司 | 一种定性检测hla-b27的试剂盒及其检测方法 |
| WO2022216832A1 (en) * | 2021-04-07 | 2022-10-13 | Regeneron Pharmaceuticals, Inc. | A composition for use in treating mhc-1-opathies |
| US12157891B2 (en) * | 2021-10-14 | 2024-12-03 | Regeneron Pharmaceuticals, Inc. | Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors |
| WO2023220263A1 (en) * | 2022-05-13 | 2023-11-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for modulating tcr |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340610C (en) * | 1985-08-16 | 1999-06-29 | Karen A. Nelson | Monoclonal antibody to polymorphic hla determinant-b27 |
| US5369010A (en) | 1985-08-16 | 1994-11-29 | Genetic Systems Corporation | Monoclonal antibody to polymorphic HLA determinant -B27 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| US20130315933A1 (en) | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
-
2013
- 2013-04-01 TW TW102111629A patent/TWI619729B/zh not_active IP Right Cessation
- 2013-04-02 EA EA201491827A patent/EA201491827A1/ru unknown
- 2013-04-02 CN CN201380015594.7A patent/CN104169302A/zh active Pending
- 2013-04-02 MX MX2014011898A patent/MX365690B/es active IP Right Grant
- 2013-04-02 CA CA2868907A patent/CA2868907C/en active Active
- 2013-04-02 JP JP2015504677A patent/JP6320993B2/ja active Active
- 2013-04-02 EP EP13716138.6A patent/EP2834272B1/en active Active
- 2013-04-02 KR KR20147030831A patent/KR20150003256A/ko not_active Withdrawn
- 2013-04-02 BR BR112014024622A patent/BR112014024622A2/pt not_active IP Right Cessation
- 2013-04-02 UY UY0001034721A patent/UY34721A/es not_active Application Discontinuation
- 2013-04-02 MY MYPI2014002668A patent/MY171180A/en unknown
- 2013-04-02 HK HK15107698.3A patent/HK1207092A1/xx unknown
- 2013-04-02 WO PCT/US2013/034952 patent/WO2013152001A2/en not_active Ceased
- 2013-04-02 US US13/855,448 patent/US9790273B2/en not_active Expired - Fee Related
- 2013-04-02 AU AU2013243644A patent/AU2013243644C1/en not_active Ceased
- 2013-04-02 SG SG11201405759UA patent/SG11201405759UA/en unknown
- 2013-04-02 NZ NZ700650A patent/NZ700650A/en not_active IP Right Cessation
- 2013-04-02 SG SG10201608136SA patent/SG10201608136SA/en unknown
- 2013-04-03 AR ARP130101081A patent/AR090585A1/es unknown
-
2014
- 2014-09-17 IL IL234707A patent/IL234707A0/en unknown
- 2014-09-29 PH PH12014502184A patent/PH12014502184A1/en unknown
- 2014-09-30 CL CL2014002631A patent/CL2014002631A1/es unknown
- 2014-10-30 CO CO14241139A patent/CO7121320A2/es unknown
-
2018
- 2018-01-03 IL IL256716A patent/IL256716A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514110A5 (OSRAM) | ||
| JP2017505125A5 (OSRAM) | ||
| JP2013542194A5 (OSRAM) | ||
| JP2015503909A5 (OSRAM) | ||
| JP2015535828A5 (OSRAM) | ||
| SI3042917T1 (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| JP2018500014A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| JP2018021031A5 (OSRAM) | ||
| JP2016507470A5 (OSRAM) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2018536393A5 (OSRAM) | ||
| JP2012523417A5 (OSRAM) | ||
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| JP2015525795A5 (OSRAM) | ||
| JP2013542191A5 (OSRAM) | ||
| JP2011509245A5 (OSRAM) | ||
| JP2025131696A5 (OSRAM) | ||
| JP2018507220A5 (OSRAM) | ||
| JP2016519650A5 (OSRAM) | ||
| ME02798B (me) | Protutijela protiv dkk-1" | |
| JP2014205674A5 (OSRAM) | ||
| JP2023055904A5 (OSRAM) | ||
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их |